Abstract
Objective
Data is scarce concerning ganciclovir, used in CMV-related diseases in transplant patient with renal failure, especially when dialysis is necessary.
Design
Prospective trial.
Setting
Intensive care unit in a university hospital, and pharmacy laboratory.
Patients
Pharmacokinetics were obtained in 3 patients undergoing continuous veno-venous hemodialysis (CVVHD) (PAN 69).
Interventions
HPLC measurements of plasmatic and ultrafiltrated ganciclovir were determined at 17 times intervals after a 5 mg/kg every 48 h dosage.
Results
Peak and trough concentrations were respectively 16.1±2.4 and 5.5±0.5 mg/l, sieving coefficient 0.75–0.95, and volume of distribution at steady state 0.64±0.09 l/kg, half life (beta phase) 18.6±1.8 h. No direct toxicity, or CMV-related death occurred.
Conclusion
Plasma concentrations were higher than the ID 90. A dosage of 5 mg/kg/48 h of ganciclovir could be used during CVVHD, and ideally adjusted to monitoring of plasma drug levels.
This is a preview of subscription content, log in via an institution to check access.
References
Keay S, Petersen E, Icenogle T, Zeluff B, Samo T, Busch D, Newman C, Buhles W, Merigan T (1988) Ganciclovir treatment of serious cytomegalovirus infection in heart and heart lung transplant recipients. Rev Infect Dis 10:S563-S572
Lake K, Fletcher C, Love K, Brown D, Joyce L, Pritzker M (1988) Ganciclovir pharmacokinetics during renal impairment. Antimicrob Agents Chemother 32:1899–1900
Golper TA, Wedel S, Kaplan A, Saad A, Donta S, Paganini E (1985) Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations. Int J Artif Organs 8:307–312
Boulieu R, Bleyzac N, Ferry S (1991) High performance liquid chromatographic determination of ganciclovir in plasma. J Chromatogr Biomed Appl 567:480–484
Bickley S (1988) Drug dosing during continuous arteriovenous hemofiltration. Clin Pharm 7:198–206
Capparelli E, Lane J, Sonke R, Connor J (1991) Ganciclovir pharmacokinetics. In: Spector (1991) Ganciclovir therapy for CMV. Dekker, New York, p 71–81
Rondeau E, Farquet C, Fries D, Sraer JD (1990) Pharmacocinetique du ganciclovir chez les transplantés rénaux. La lettre de l'Infectiologie Févier: S22–S26
Swan S, Munar M, Wigger M, Bennett W (1991) A pharmacokinetics of ganciclovir in a patient undergoing hemodialysis. Am J Kidney Dis XVII:69–72
Gomeni C, Gomeni R (1987) SIPHAR. An integrated computer system for statistical and pharmacokinetic data analysis. Proceedings of the 7th International Congress of Medical Information, Rome, 21–25 Sept 1987
Sommadossi JP, Bevan R, Ling T, Lee F, Mastre B, Chaplin M, Nerenberg C, Koretz S, Buhles W (1988) Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev Infect Dis 10:S507-S514
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bastien, O., Boulieu, R., Bleyzac, N. et al. Clinical use of ganciclovir during renal failure and continuous hemodialysis. Intensive Care Med 20, 47–48 (1994). https://doi.org/10.1007/BF02425056
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02425056